



BRIDGING THE GAP

Advancing Prostate Cancer Excellence in France

EXECUTIVE SUMMARY

France has developed a robust and comprehensive prostate cancer care framework, characterized by widespread screening access, advanced diagnostic capabilities, equitable treatment availability, and integrated survivorship care. While patient outcomes are among the best in Europe, disparities persist between urban and rural regions, and there is scope to further personalize treatment through wider use of molecular diagnostics.


This policy brief reviews the strengths of France's prostate cancer system, identifies remaining gaps, and outlines targeted reforms to sustain progress and innovation in a **Level 4 – Advanced** maturity context.

INTRODUCTION

Sustaining Excellence While Closing Equity Gaps

Prostate cancer is the most frequently diagnosed cancer in French men, supported by strong public health programs, organized screening, and advanced treatment services. France's universal healthcare system provides comprehensive coverage, significantly reducing financial barriers to care.

However, geographic variations in access to cutting-edge therapies and uneven participation in screening programs remain challenges. At **Level 4 maturity**, France's focus must shift from building core capacity to optimizing equity, innovation, and personalized care pathways.



France Ranks at Level 4 – Advanced Prostate Cancer Maturity Framework



PROSTATE CANCER IN FRANCE


Current Landscape and Strategic Gaps

Pillar	Current Status	Strength	Policy Action
Early Detection & Diagnosis	PSA testing is widely available and reimbursed; shared decision-making models guide screening in men aged 50–75.	High population awareness and strong GP-led preventive care system.	Increase outreach in rural and underserved areas to raise participation and ensure timely follow-up after abnormal results.
Biomarker & Molecular Testing	Access to advanced biomarkers and genomic profiling is available in major cancer centers but less so in smaller hospitals.	Strong research infrastructure and integration with oncology networks.	Expand molecular diagnostics to regional hospitals and standardize access through national guidelines.
Treatment Access	Comprehensive access to surgery, radiotherapy, brachytherapy, chemotherapy, and hormonal therapy across public and private facilities.	Universal coverage under France’s social security system ensures affordability.	Invest in tele-oncology and satellite clinics to improve access in remote areas; maintain capacity for new therapies such as next-gen radioligands.
Clinical Guidelines	National evidence-based guidelines developed and updated regularly by the French Urology Association and INCa.	Strong adherence across institutions and continuous professional development.	Further integrate personalized medicine approaches and AI-driven decision tools into guidelines.
Palliative & Survivorship Care	Well-established palliative care services integrated into oncology pathways, with survivorship programs for long-term quality of life.	Comprehensive network of community palliative teams and psychological support services.	Expand survivorship research and support programs to address late treatment effects and psychosocial needs.



CONCLUSION & Call to Action

France's prostate cancer care system demonstrates high maturity with excellent patient outcomes and strong institutional capacity. The remaining challenge is to ensure uniform access to innovations and services across all regions, eliminating urban-rural disparities and accelerating the uptake of precision medicine approaches.



CONCLUSION

With **Level 4 - Advanced maturity**, France stands as a model of comprehensive, equitable prostate cancer care. The country's challenge is no longer basic capacity but sustained innovation, equity, and personalization. By closing geographic gaps, accelerating molecular diagnostics adoption, and integrating emerging therapies, France can further cement its position as a leader in prostate cancer management. Continued investment in research, patient engagement, and digital solutions will ensure that every man in France benefits from the highest standard of care, regardless of where he lives.